PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study

Faculty Opinions recommendation of FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717997102.793478384 ◽

2013 ◽

Author(s):

Sabine Tejpar ◽

Loredana Vecchione

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Download Full-text

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

ESMO Open ◽

10.1016/j.esmoop.2021.100062 ◽

2021 ◽

Vol 6 (2) ◽

pp. 100062

Author(s):

J. Sastre ◽

P. García-Alfonso ◽

J.M. Viéitez ◽

M.T. Cano ◽

F. Rivera ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Phase Ii ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Wild Type ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Pik3ca Mutations ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

Ophthalmology ◽

10.1016/j.ophtha.2019.01.024 ◽

2019 ◽

Vol 126 (6) ◽

pp. 792-800 ◽

Cited By ~ 7

Author(s):

David L. Wirta ◽

Gail L. Torkildsen ◽

Helen R. Moreira ◽

John D. Lonsdale ◽

Joseph B. Ciolino ◽

...

Keyword(s):

Phase Ii ◽

Dry Eye ◽

Phase Ii Study ◽

Dry Eye Disease ◽

Eye Disease ◽

Clinical Phase

Download Full-text

Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3109-4 ◽

2016 ◽

Vol 78 (3) ◽

pp. 585-593 ◽

Cited By ~ 3

Author(s):

Takao Takahashi ◽

◽

Yasunori Emi ◽

Eiji Oki ◽

Kazuma Kobayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Exon 2 ◽

Multicenter Phase ◽

Previously Treated ◽

Kras Exon

Download Full-text

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

Annals of Oncology ◽

10.1093/annonc/mds008 ◽

2012 ◽

Vol 23 (9) ◽

pp. 2341-2346 ◽

Cited By ~ 60

Author(s):

L.H. Jensen ◽

J. Lindebjerg ◽

J. Ploen ◽

T.F. Hansen ◽

A. Jakobsen

Keyword(s):

Biliary Tract ◽

Phase Ii ◽

Biliary Tract Cancer ◽

Wild Type ◽

Tract Cancer

Download Full-text

RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djv404 ◽

2016 ◽

Vol 108 (3) ◽

pp. djv404

Author(s):

He Wen-zhuo ◽

Xia Liang-ping

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Wild Type ◽

Randomized Phase Ii

Download Full-text

Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial

Radiotherapy and Oncology ◽

10.1016/j.radonc.2004.01.007 ◽

2004 ◽

Vol 71 (2) ◽

pp. 157-162 ◽

Cited By ~ 13

Author(s):

Gui-Yuan Chen ◽

Guo-Liang Jiang ◽

Hao Qian ◽

Li-Juan Wang ◽

Hua-Jun Yang ◽

...

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

Clinical Phase ◽

Accelerated Radiation Therapy

Download Full-text

478TiP A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Annals of Oncology ◽

10.1093/annonc/mdv532.62 ◽

2015 ◽

Vol 26 ◽

pp. ix125

Author(s):

J. Wolf ◽

M. Hochmair ◽

J.G. Kattan ◽

M.-K. Ang ◽

E.B. Garon ◽

...

Keyword(s):

Cohort Study ◽

Phase Ii ◽

Metastatic Disease ◽

Systemic Therapy ◽

Advanced Nsclc ◽

Wild Type

Download Full-text

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Annals of Oncology ◽

10.1093/annonc/mdt116 ◽

2013 ◽

Vol 24 (7) ◽

pp. 1769-1777 ◽

Cited By ~ 27

Author(s):

T. Brodowicz ◽

T.E. Ciuleanu ◽

D. Radosavljevic ◽

E. Shacham-Shmueli ◽

D. Vrbanec ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text